The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chernyaev A.L.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution «Petrovsky National Research Centre Of Surgery»

Tsareva N.A.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Avdeev S.N.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Samsonova M.V.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
A.S. Loginov Moscow State Clinical and Research Center Moscow Healthcare Department

Portopulmonary hypertension

Authors:

Chernyaev A.L., Tsareva N.A., Avdeev S.N., Samsonova M.V.

More about the authors

Journal: Journal of Respiratory Medicine. 2025;1(2): 39‑44

DOI: 10.17116/respmed2025102139

Read: 726 times

Download PDF (RU)
Contact the author
Table of contents

PORTOPULMONARY HYPERTENSION
PORTOPULMONARY HYPERTENSION

To cite this article:

Chernyaev AL, Tsareva NA, Avdeev SN, Samsonova MV. Portopulmonary hypertension. Journal of Respiratory Medicine. 2025;1(2):39‑44. (In Russ.)
https://doi.org/10.17116/respmed2025102139

Подписка 2026 Респираторная медицина (Journal of Respiratory Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Unre­solved problem: Chemotherapy-Induced Peri­pheral Neuropathy. P.A. Herzen Journal of Onco­logy. 2024;(5):76-81
Quality asse­ssment of health care deli­very to patients with sexually transmitted infe­ctions in dermatovenereological institutions of Moscow acco­rding to medi­cal reco­rds analysis. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):503-509
Psoriasis in pregnant women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):517-524
Tube­rculous otitis media in an adolescent. Clinical case. Russian Bulletin of Otorhinolaryngology. 2024;(5):63-66
Modern view on the etiology of gallstone disease in children. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):59-68
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Comparative analysis of the resu­lts of treatment of gastric polyps by methods of loop electroexcision, laser and endo­scopic poly­pectomy with aspi­ration capture. Endo­scopic Surgery. 2024;(6):24-30
Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):709-712
Motor beha­vior in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mice model of Parkinson’s disease treated with reco­mbinant spidroin rS1/9 microgel. Mole­cular Gene­tics, Microbiology and Viro­logy. 2024;(4):12-17
Clinical and epidemiological indi­cators of stroke during the COVID-19 pandemic and in the post-COVID period in the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):5-11
Abstract:

The article is devoted to the review of literature data on portopulmonary hypertension. The data on the occurrence of this pathology among people with liver diseases, as well as among patients with pulmonary hypertension are presented. Modern concepts of the pathogenesis of the disease, including genetic disorders, are described. Treatment strategies for portopulmonary hypertension at the present stage coincide with those for pulmonary arterial hypertension, but further studies are needed to assess the effectiveness of various drugs in this pathology. Mortality in portopulmonary hypertension is higher than in pulmonary hypertension. Combination of drug therapy with liver transplantation leads to a more favorable prognosis than either of these options alone. The decision to perform a transplant requires the work of a multidisciplinary team of specialists.

Keywords:

portopulmonary hypertension
pathogenesis
treatment
transplantation

Authors:

Chernyaev A.L.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution «Petrovsky National Research Centre Of Surgery»

Tsareva N.A.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Avdeev S.N.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Samsonova M.V.

Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia;
A.S. Loginov Moscow State Clinical and Research Center Moscow Healthcare Department

Received:

05.05.2025

Accepted:

13.05.2025

Close metadata

References:

  1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237
  2. Avdeev SN, Gainitdinova VV, Neklyudova GV, Tsareva NA, Gneusheva TYu. Idiopathic pulmonary arterial hypertension. Study guide. M.; 2024. (In Russ.).
  3. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. https://doi.org/10.1183/13993003.01913-2018
  4. Mantz FA Jr, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol. 1951;52(1):91-97. 
  5. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology. 2006;44(6):1502-1510. https://doi.org/10.1002/hep.21431
  6. Liberal R, Grant CR, Baptista R, Macedo G. Porto-pulmonary hypertension: a comprehensive review. Clin Res Hepatol Gastroenterol. 2015;39(2):157-167.  https://doi.org/10.1016/j.clinre.2014.12.011
  7. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Committee ERSTFP-HVDS. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004;24(5):861-880.  https://doi.org/10.1183/09031936.04.00010904
  8. Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, Chaouat A, Picard F, Horeau-Langlard D, Bourdin A, Jutant EM, Beurnier A, Jevnikar M, Jaïs X, Simonneau G, Montani D, Sitbon O, Humbert M. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022;59:2102419. https://doi.org/10.1183/13993003.02419-2021
  9. Savale L, Magnier R, Le Pavec J, Jaïs X, Montani D, O’Callaghan DS, Humbert M, Dingemanse J, Simonneau G, Sitbon O. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J. 2013;41:96-103.  https://doi.org/10.1183/09031936.00117511
  10. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171.  https://doi.org/10.1016/j.jhep.2018.09.014
  11. Li N, Wu Q, Meng J, Feng C, Jiang S, Chen M, Xu W, Wang F, Zhang Y, Liu J, Xu C, Liu G, Gao H. Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review. ESC Heart Failure. 2023;10:2718-2721. https://doi.org/10.1002/ehf2.14431
  12. Mancuso L, Scordato F, Pieri M, Valerio E, Mancuso A. Management of portopulmonary hypertension: New perspectives. World J Gastroenterol. 2013;19(45):8252-8257. https://doi.org/10.3748/wjg.v19.i45.8252
  13. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg. 1997;3(5):494-500.  https://doi.org/10.1002/lt.500030503
  14. Hua R, Sun YW, Wu ZY, Cheng W, Xu Q, Cao H, Luo M. Role of 2-dimensional Doppler echocardiography in screening portopulmonary hypertension in portal hypertension patients. Hepatobiliary Pancreat Dis Int. 2009;8(2):157-161. 
  15. Al-Harbi A, Abdullah K, Al-Abdulkareem A, Alghamdi A, Al-Jahdali H. Prevalence of portopulmonary hypertension among liver transplant candidates in a region highly endemic for viral hepatitis. Ann Transplant. 2014;19:1-5.  https://doi.org/10.12659/aot.889645
  16. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS Jr, Fallon MB; Pulmonary Vascular Complications of Liver Disease Study Group. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48(1):196-203.  https://doi.org/10.1002/hep.22275
  17. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Bernuau J, Marty J, Lebrec D, Valla D, Durand F. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37(2):401-409.  https://doi.org/10.1053/jhep.2003.50060
  18. Krowka MJ, Edwards WD. A spectrum of pulmonary vascular pathology in portopulmonary hypertension. Liver Transpl. 2000;6(2):241-242.  https://doi.org/10.1002/lt.500060209
  19. Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med. 1996;17(1):1-15.  https://doi.org/10.1016/s0272-5231(05)70295-1
  20. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):25S-32S.  https://doi.org/10.1016/j.jacc.2004.02.033
  21. Rodriguez-Vilarrupla A, Fernandez M, Bosch J, Garcia-Pagan JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol. 2007;6(1):28-36. 
  22. Pellicelli AM, Barbaro G, Puoti C, Guarascio P, Lusi EA, Bellis L, D’Ambrosio C, Villani R, Vennarecci G, Liotta G, Ettore G, Andreoli A. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology. 2010;61(8):802-806.  https://doi.org/10.1177/0003319710369101
  23. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52(9):1355-1362. https://doi.org/10.1136/gut.52.9.1355
  24. Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem. 1994;269(13):10112-10118.
  25. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227-237.  https://doi.org/10.1016/j.cardiores.2003.11.026
  26. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159(6):1925-1932. https://doi.org/10.1164/ajrccm.159.6.9804054
  27. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Kawut SM; Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179(9):835-842.  https://doi.org/10.1164/rccm.200809-1472oc
  28. Chen H, Wang F, Xiao J, Qi X, Yang F, Wang L, Yang C. Natural killer cell-mediated immune deficiency or compromise in patients with portopulmonary hypertension. Arch Med Sci. 2014;10(5):1055-1056. https://doi.org/10.5114/aoms.2014.46225
  29. Fallon Mb, Abrams Ga, Mcgrath Jw, Hou Z, Luo B. Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiol. 1997;272(4 Pt 1):G779-G784. https://doi.org/10.1152/ajpgi.1997.272.4.g779
  30. Raevens S, Geerts A, Paridaens A, Lefere S, Verhelst X, Hoorens A, Van Dorpe J, Maes T, Bracke KR, Casteleyn C, Jonckx B, Horvatits T, Fuhrmann V, Van Vlierberghe H, Van Steenkiste C, Devisscher L, Colle I. Placental growth factor inhibition targets pulmonary angiogenesis and represents a novel therapy for hepatopulmonary syndrome in mice. Hepatology. 2018;68(2):634-651.  https://doi.org/10.1002/hep.29579
  31. Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, Horeau-Langlard D, Tromeur C, Chabanne C, Prevot G, Chaouat A, Moceri P, Artaud-Macari É, Degano B, Tresorier R, Boissin C, Bouvaist H, Simon AC, Riou M, Favrolt N, Palat S, Bourlier D, Magro P, Cottin V, Bergot E, Lamblin N, Jaïs X, Coilly A, Durand F, Francoz C, Conti F, Hervé P, Simonneau G, Montani D, Duclos-Vallée JC, Samuel D, Humbert M, De Groote P, Sitbon O. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol. 2020;73:130-139.  https://doi.org/10.1016/j.jhep.2020.02.021
  32. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest. 2011;139:109-114.  https://doi.org/10.1378/chest.10-0574
  33. Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin N, Savale L, Krowka M. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7(7):594-604.  https://doi.org/10.1016/S2213-2600(19)30091-8
  34. Rossi R, Talarico M, Schepis F, Coppi F, Sgura FA, Monopoli DE, Minici R, Boriani G. Effects of sildenafil on right ventricle remodelling in portopulmonary hypertension. Pulm Pharmacol Ther. 2021;70:102071. https://doi.org/10.1016/j.pupt.2021.102071
  35. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, Jaïs X, Yaïci A, Humbert M, Simonneau G, Sitbon O. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178(6):637-643.  https://doi.org/10.1164/rccm.200804-613oc
  36. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445-2453. https://doi.org/10.1111/j.1600-6143.2008.02384.x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.